Angle Aktie - AGL

Professionelle Tools für Privatanleger.

Premium

Current Price

15,00

Gebot

14,50

Fragen

15,50

Volumen

11.450.815

13,75 Tagesbereich 16,25

7,25 52-Wochen-Bereich 25,00

Marktkapitalisierung

48,396M

Handelsende

13,25

Handelsbeginn

13,75

Letzte Trade

25000

15.08

(O)

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

1.356.045

Ausgegebene Aktien

322.641.668

Dividendenrendite

Kurs-Gewinn-Verhältnis

-2,40

Gewinn pro Aktie (EPS)

-0,06

Erlöse

2,19M

Nettogewinn

-20,13M

Sektor

Business Services, Nec

Branche

Business Consulting

Website

www.angleplc.com

Hauptsitz

Guildford, Gbr

Gegründet

2003

Angle Plc is listed in the Business Services sector of the Londoner Börse with ticker AGL. The last closing price for Angle was 13,25p. Over the last year, Angle shares have traded in a share price range of 7,25p to 25,00p.

Angle currently has 322.641.668 shares in issue. The market capitalisation of Angle is £42,75 million. Angle has a price to earnings ratio (PE ratio) of -2.40.

Angle reports breakthrough in dual cancer DNA analysis

Angle PLC on Wednesday released successful results from its new dual circulating tumour DNA and circulating tumour ce ...

Angle PLC Analysis of CTC-DNA and ctDNA using Illumina assay

Angle PLC 29 January 2025 For immediate release 29 January 2025 ANGLE plc ("the Company") NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing...

Angle fails to win market confidence despite narrowing loss in 2024

Angle PLC on Thursday said it expected losses to have narrowed in 2024, but its share price suggested lingering marke ...

Angle PLC Trading Update

Angle PLC 23 January 2025 For immediate release 23 January 2025 ANGLE plc ("the Company") TRADING UPDATE Revenue for 2024 expected to be up 31% Lower cost base going into 2025 with a...

Angle stock surges as firm showcases new assay products

Angle PLC on Friday said it is has presented data that highlights the potential of a new assay for lung cancer patien ...

Angle notes use of Parsortix system in treatment resistance study

Angle PLC on Monday said its in-vitro diagnostic Parsortix system was successfully used in a non-small cell lung canc ...

EARNINGS: Ebiquity bemoans poor conditions on swing to interim loss

The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported b ...

Angle PLC Half-year Report

Angle PLC 26 September 2024 For Immediate Release 26 September 2024 ANGLE plc ("ANGLE" or "the Company") Interim Results for the six months ended 30 June 2024 LARGE PHARMA STRATEGY...

Angle PLC Exclusive agreement for DNA NGS panel

Angle PLC 23 September 2024 For immediate release 23 September 2024 ANGLE plc ("the Company") ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBE Option for...

IN BRIEF: Angle celebrates agreement with Recursion Pharmaceuticals

ford, England-based liquid biopsy company - Announces it has signed an agreement with Recursion Pharmaceuticals Inc, a ...

Angle reports breakthrough in dual cancer DNA analysis

Angle PLC on Wednesday released successful results from its new dual circulating tumour DNA and circulating tumour ce ...

Angle PLC Analysis of CTC-DNA and ctDNA using Illumina assay

Angle PLC 29 January 2025 For immediate release 29 January 2025 ANGLE plc ("the Company") NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing...

Angle fails to win market confidence despite narrowing loss in 2024

Angle PLC on Thursday said it expected losses to have narrowed in 2024, but its share price suggested lingering marke ...

Angle PLC Trading Update

Angle PLC 23 January 2025 For immediate release 23 January 2025 ANGLE plc ("the Company") TRADING UPDATE Revenue for 2024 expected to be up 31% Lower cost base going into 2025 with a...

Angle stock surges as firm showcases new assay products

Angle PLC on Friday said it is has presented data that highlights the potential of a new assay for lung cancer patien ...

Angle notes use of Parsortix system in treatment resistance study

Angle PLC on Monday said its in-vitro diagnostic Parsortix system was successfully used in a non-small cell lung canc ...

EARNINGS: Ebiquity bemoans poor conditions on swing to interim loss

The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported b ...

Angle PLC Half-year Report

Angle PLC 26 September 2024 For Immediate Release 26 September 2024 ANGLE plc ("ANGLE" or "the Company") Interim Results for the six months ended 30 June 2024 LARGE PHARMA STRATEGY...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	2.5	20	12.5	16.25	11.25	2836477	13.04377168	DE
4	4.75	46.3414634146	10.25	16.25	10.25	1276894	12.435787	DE
12	7	87.5	8	16.25	7.75	1356045	11.08314458	DE
26	0.375	2.5641025641	14.625	16.25	7.25	1122995	10.73600186	DE
52	-2.5	-14.2857142857	17.5	25	7.25	1393864	14.08708615	DE
156	-101	-87.0689655172	116	163.5	7.25	1572702	29.90909036	DE
260	-58	-79.4520547945	73	163.5	7.25	1231334	42.13662436	DE

AGL - Frequently Asked Questions (FAQ)

What is the current Angle share price?

The current share price of Angle is 15,00p

How many Angle shares are in issue?

Angle has 322.641.668 shares in issue

What is the market cap of Angle?

The market capitalisation of Angle is GBP 42,75M

What is the 1 year trading range for Angle share price?

Angle has traded in the range of 7,25p to 25,00p during the past year

What is the PE ratio of Angle?

The price to earnings ratio of Angle is -2,4

What is the cash to sales ratio of Angle?

The cash to sales ratio of Angle is 22,06

What is the reporting currency for Angle?

Angle reports financial results in GBP

What is the latest annual turnover for Angle?

The latest annual turnover of Angle is GBP 2,19M

What is the latest annual profit for Angle?

The latest annual profit of Angle is GBP -20,13M

What is the registered address of Angle?

The registered address for Angle is 10 NUGENT ROAD, THE SURREY RESEARCH PARK, GUILDFORD, GU2 7AF

What is the Angle website address?

The website address for Angle is www.angleplc.com

Which industry sector does Angle operate in?

Angle operates in the BUSINESS CONSULTING sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
MACMarechale Capital Plc	3,80p (117,14%)	36,92M
DKEDukemount Capital Plc	0,045p (42,86%)	887,24M
SCGLSealand Capital Galaxy Limited	7,75p (33,62%)	12,22M
OBDOxford Biodynamics Plc	0,65p (30,00%)	5,03M
BKYBerkeley Energia Limited	19,25p (20,31%)	989,93k
NFXNuformix Plc	0,09p (-37,93%)	249,96M
PPSProton Motor Power Systems Plc	0,225p (-25,00%)	983,97k
VASTVast Resources Plc	0,115p (-19,30%)	183,06M
GSCGs Chain Plc	1,30p (-16,13%)	629k
SYMESupply@me Capital Plc	0,0026p (-16,13%)	144,24M
DKEDukemount Capital Plc	0,045p (42,86%)	887,24M
NTVONativo Resources Plc	0,0019p (0,00%)	467,88M
INSPInspirit Energy Holdings Plc	0,0029p (11,54%)	429,63M
MSMNMosman Oil And Gas Limited	0,025p (-3,85%)	357,22M
TRPTower Resources Plc	0,0285p (-3,39%)	301,56M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Angle Plc (AGL)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Angle Plc

AGL Neueste Nachrichten

Angle reports breakthrough in dual cancer DNA analysis

Angle PLC Analysis of CTC-DNA and ctDNA using Illumina assay

Angle fails to win market confidence despite narrowing loss in 2024

Angle PLC Trading Update

Angle stock surges as firm showcases new assay products

Angle notes use of Parsortix system in treatment resistance study

EARNINGS: Ebiquity bemoans poor conditions on swing to interim loss

Angle PLC Half-year Report

Angle PLC Exclusive agreement for DNA NGS panel

IN BRIEF: Angle celebrates agreement with Recursion Pharmaceuticals

Angle reports breakthrough in dual cancer DNA analysis

Angle PLC Analysis of CTC-DNA and ctDNA using Illumina assay

Angle fails to win market confidence despite narrowing loss in 2024

Angle PLC Trading Update

Angle stock surges as firm showcases new assay products

Angle notes use of Parsortix system in treatment resistance study

EARNINGS: Ebiquity bemoans poor conditions on swing to interim loss

Angle PLC Half-year Report

AGL - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Angle Plc (AGL) Börsenkurse

Angle Plc (AGL)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Angle Plc

AGL Neueste Nachrichten

AGL - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen